Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.96 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.96 |
| ▸ | HTR1A | P08908 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | DRD3 | P35462 | 2/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | HTR7 | P34969 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylephrine SCHEMBL30800718 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL21829033 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL29382859 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL412215 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL5053821 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL30104947 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL24655 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL24654 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL5958774 | 0.98 | HIF1A (0.97) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL4711 | 0.98 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957646-B2 | Methods and compositions of stable phenylephrine formulations | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-04-16 | — | — | US | claimed |
| US-20170281786-A1 | COMPOSITIONS AND METHODS OF MAKING RAPIDLY DISSOLVING IONICALLY MASKED FORMULATIONS | NEOS THERAPEUTICS, LP | 2017-10-05 | — | — | US | disclosed |
| US-9522120-B2 | Compositions and methods of making sustained release liquid formulations | NEOS THERAPEUTICS, LP (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150004240-A1 | COMPOSITIONS AND METHODS OF MAKING RAPIDLY DISSOLVING IONICALLY MASKED FORMULATIONS | PFAB LP | 2015-01-01 | — | — | US | disclosed |
| US-8840924-B2 | Compositions and methods of making rapidly dissolving ionically masked formulations | NEOS THERAPEUTICS, LP (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130084340-A1 | Compositions and Methods of Making Sustained Release Liquid Formulations | NEOS THERAPEUTICS, LP (US) | 2013-04-04 | — | — | US | disclosed |
| US-8318210-B2 | Compositions and methods of making sustained release liquid formulations | NEOS THERAPEUTICS, LP (US) | 2012-11-27 | — | — | US | disclosed |
| US-8313770-B2 | Modifying drug release in suspensions of ionic resin systems | NEOS THERAPEUTICS, LP (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100278901-A1 | COMPOSITIONS AND METHODS OF MAKING RAPIDLY DISSOLVING IONICALLY MASKED FORMULATIONS | NEOS THERAPEUTICS, LP (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2164631-A1 | MODIFYING DRUG RELEASE IN SUSPENSIONS OF IONIC RESIN SYSTEMS | Neos Therapeutics, LP (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090011027-A1 | Modifying Drug Release in Suspensions of Ionic Resin Systems | NEOS THERAPEUTICS, LP (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008151071-A1 | MODIFYING DRUG RELEASE IN SUSPENSIONS OF IONIC RESIN SYSTEMS | NEOS THERAPEUTICS, LP (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1855613-A2 | COMPOSITIONS AND METHODS OF MAKING SUSTAINED RELEASE LIQUID FORMULATIONS | Neos Therapeutics, LP (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070092553-A1 | Compositions and methods of making rapidly dissolving lonically masked formulations | PFAB LP (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2006093838-A2 | COMPOSITIONS AND METHODS OF MAKING SUSTAINED RELEASE LIQUID FORMULATIONS | NEOS THERAPEUTICS, LP (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060193877-A1 | Compositions and methods of making sustained release liquid formulations | PFAB, LP (US) | 2006-08-31 | — | — | US | disclosed |
| US-20060148837-A1 | Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | EVERETT LABORATORIES, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20050152967-A1 | Dynamic variable release | PFAB, LP (US) | 2005-07-14 | — | — | US | disclosed |
| US-4681940-A | ANTIALLERGENS, ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0226342-A1 | 5-Phenyl-2-oxazole derivatives as anti-inflammatory/antiallergic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957646-B2 | Methods and compositions of stable phenylephrine formulations | ADRA2C, ADRA1A, ADRB1 | ADRA1A 2/4885ADRA1B 6/4885ADRA1D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.